AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26864194
Drug: Rocuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.3 mg·kg(-1)
Trial: 26865277
Drug: miR-92a inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: miR-92a inhibitors
Trial: 26865594
Drug: 4-IM (3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-IM (3-dose IM priming with a single booster at 42 months)
Trial: 26865594
Drug: 5-IM (3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-IM (3-dose IM priming with boosters at 18 and 42 months)
Trial: 26865594
Drug: 7-IM (3-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-IM (3-dose IM priming with boosters at 12, 18, 30, and 42 months)
Trial: 26865594
Drug: 8-SQ (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-SQ (licensed priming series of 6 doses with two annual boosters administered subcutaneously)
Trial: 26865594
Drug: 8-IM (licensed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-IM (licensed priming series of 6 doses with two annual boosters administered intramuscularly)
Trial: 26866015
Drug: AFFITOPE® AD02
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AFFITOPE® AD02 (amyloid-beta-targeting vaccine)
Trial: 26868114
Drug: DAIR treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAIR treatment
Trial: 26868433
Drug: Genetic variation
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetic variation at ENPP1 locus (rs858340-G)
Trial: 26868433
Drug: Insulin sensitivity
RxNorm normalized name: Fluorimax Sensitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin sensitivity assessment via euglycaemic insulin clamp
Trial: 26868955
Drug: NAL-NL2 prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NAL-NL2 prescription rule
Trial: 26869376
Drug: 5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 μg dose of glycoconjugate GBS vaccine (serotypes Ia, Ib, and III, with CRM197) administered intramuscularly at 24-35 weeks' gestation.
Trial: 26869532
Drug: Dengue IgG-antibodies
RxNorm normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dengue IgG-antibodies
Trial: 26869532
Drug: Chikungunya IgG-antibodies
RxNorm normalized name: CHIKUNGUNYA VACCINE
DrugBank: Chikungunya vaccine (live, attenuated) (DB18701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chikungunya IgG-antibodies
Trial: 26869690
Drug: Ribavirin +
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin + Abacavir (300 mg orally every 12 h)
Trial: 26869690
Drug: Ribavirin alone
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ribavirin alone (weight-based dosing)
Trial: 26870152
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose of multivitamins/minerals
Trial: 26870152
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of multivitamins/minerals
Trial: 26870733
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of palonosetron 0.075 mg IV, dexamethasone 10 mg IV, and promethazine 25 mg IV
Trial: 26870733
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy of palonosetron, dexamethasone, and promethazine
Trial: 26871197
Drug: Low-dose imatinib
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose imatinib plus nilotinib
Trial: 26871769
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of LncPPARδ and risk factors
Trial: 26871943
Drug: Integration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integration of alcohol treatment into TB treatment
Trial: 26871943
Drug: Drug addiction
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR SUBSTANCE ADDICTION TREATMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug addiction
Trial: 26873642
Drug: Alisertib 50
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib 50 mg orally BID for 7 days with 14 days rest until disease progression
Trial: 26873687
Drug: Cardiac resynchronization
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardiac resynchronization therapy in women
Trial: 26876245
Drug: Deferasirox (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferasirox (20 mg·kg(-1)·d(-1))
Trial: 26877119
Drug: Exposure treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure treatment guided by the therapist
Trial: 26880867
Drug: Neoadjuvant radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiation with DC injections (50 Gy of external beam radiation in 25 fractions, 4 intratumoral injections of DCs)
Trial: 26880867
Drug: Neoadjuvant radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radiation with DC injections
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 14 days
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 28 days
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 56 days
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 112 days
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 365 days
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score ≥2
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 365 days in patients with CHADS2 score of 1
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden ≥0.044 hours/day
Trial: 26882334
Drug: Daily snapshot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily snapshot ECG monitoring over 365 days in patients with AT/AF burden <0.044 hours/day
Trial: 26882907
Drug: Increase in
RxNorm normalized name: Incruse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increase in lymphocyte density after chemotherapy
Trial: 26882910
Drug: Sildenafil 50
RxNorm normalized name: sildenafil 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 50 mg administered orally
Trial: 26883498
Drug: Clopidogrel (plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (plus aspirin)
Trial: 26884591
Drug: Entrectinib (pan-Trk
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entrectinib (pan-Trk inhibitor)
Trial: 26885381
Drug: MLE Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLE Group (5 injection sites)
Trial: 26885381
Drug: non-MLE Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: non-MLE Group (4 injection sites)
Trial: 26885675
Drug: boceprevir (BOC)-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: boceprevir (BOC)-based triple therapy
Trial: 26885686
Drug: Reduced-toxicity conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-toxicity conditioning regimen with busulfan (100 mg/m²/d for 4 days), fludarabine (30 mg/m²/d for 5 days), and anti-thymocyte globulins (2.5 mg/kg/d for 2 days)
Trial: 26886785
Drug: Antibiotic stewardship
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic stewardship programs
Trial: 26888022
Drug: Imatinib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imatinib therapy (retreatment) for a median of 16.9 months
Trial: 26888022
Drug: Longer duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer duration of imatinib before discontinuation
Trial: 26888382
Drug: Incretin based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incretin based drugs
Trial: 26888535
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor-α receptor 1 (TNF-α R1)
Trial: 26888535
Drug: Tumor necrosis
RxNorm normalized name: Tumor necrosis factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tumor necrosis factor-α receptor 1 (TNF-α R1) top quartile (>3.63 ng/L) vs bottom quartile (<2.24 ng/L)
Trial: 26888800
Drug: Platelet inhibition
RxNorm normalized name: platelet glycoprotein VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platelet inhibition (antiplatelet therapy)
Trial: 26890209
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for patients found to be deficient or initiating ART or bisphosphonate therapy
Trial: 26891037
Drug: Bryostatin-1 10
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin-1 10 μg/m
Trial: 26891037
Drug: Bryostatin-1 20
RxNorm normalized name: Bryostatin-1
DrugBank: Bryostatin 1 (DB11752)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bryostatin-1 20 μg/m
Trial: 26893170
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg intravenous melatonin
Trial: 26895949
Drug: GH replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GH replacement therapy for 6 months in the GH Rx group, dosage titrated to achieve normal IGF-1 levels.
Trial: 26895949
Drug: Non-GH replacement
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-GH replacement therapy in the non-GH Rx group.
Trial: 26897675
Drug: High on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High on-treatment platelet reactivity (HPR) defined as platelet reactivity >208 P2Y12 reaction unit
Trial: 31672031
Drug: High on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High on-treatment platelet reactivity (HPR)
Trial: 26898568
Drug: DTG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG 50 mg q24h alone
Trial: 26898568
Drug: DTG 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTG 50 mg q24h + CBZ 300 mg q12h
Trial: 26898607
Drug: Sorafenib 400mg
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sorafenib 400mg twice daily and erlotinib 150mg daily in 28-day cycles
Trial: 26901037
Drug: Total Intravenous
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total Intravenous Anaesthesia with Propofol (TIVA)
Trial: 26901163
Drug: Locoregional therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Locoregional therapies before sorafenib
Trial: 26901163
Drug: Sorafenib treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sorafenib treatment duration
Trial: 26903002
Drug: Early aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early aspirin administration
Trial: 26903277
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of ceftriaxone injection followed by 6 days of 400 mg of cefixime per day
Trial: 26903311
Drug: Panobinostat (20-60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (20-60 mg) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Trial: 26903311
Drug: Panobinostat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Panobinostat (50 mg, MTD) and epirubicin (75 mg/m² on day 5) given in 21-day cycles.
Trial: 26904207
Drug: Bronchodilator response
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bronchodilator response (BDR)
Trial: 26904404
Drug: ASP2215 (novel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASP2215 (novel FLT3-inhibitor)
Trial: 26904570
Drug: Cisplatin 30
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 30 mg/m(2)/week and paclitaxel 50 mg/m(2)/week for 5 weeks
Trial: 26904570
Drug: Cisplatin 40
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 40 mg/m(2)/week for 5 weeks (control arm)
Trial: 26907184
Drug: Ertapenem (Empirical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (Empirical Therapy)
Trial: 26907184
Drug: Other carbapenems
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other carbapenems (Empirical Therapy)
Trial: 26907184
Drug: Ertapenem (Targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ertapenem (Targeted Therapy)
Trial: 26907184
Drug: Other carbapenems
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other carbapenems (Targeted Therapy)
Trial: 26907630
Drug: CD19 CAR-T-cell
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD19 CAR-T-cell therapy
Trial: 26908063
Drug: poly(ADP-ribose) polymerase
RxNorm normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly(ADP-ribose) polymerase inhibitors
Trial: 26908089
Drug: Lurasidone (psychotropic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lurasidone (psychotropic medication)
Trial: 26908748
Drug: Recent oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recent oral sex partners (within the prior 3 months) among men
Trial: 26908748
Drug: Oral HPV
RxNorm normalized name: Adxs hpv
DrugBank: Axalimogene filolisbac (DB16692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HPV infection clearance
Trial: 26908756
Drug: FMP2.1/AS01 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FMP2.1/AS01 vaccine
Trial: 26911200
Drug: Extended CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended CRT (54Gy and 6 cycles of 5FU-based chemotherapy)
Trial: 26911200
Drug: Standard CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CRT (54Gy and 2 cycles of 5FU-based chemotherapy)
Trial: 26911408
Drug: FOLFOXIRI plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOXIRI plus panitumumab (5-FU, 3,200 mg/m(2), 48-hour continuous intravenous infusion; leucovorin, 200 mg/m(2) i.v.; irinotecan, 125 mg/m(2); oxaliplatin, 85 mg/m(2) i.v.; panitumumab, 6 mg/kg i.v.)
Trial: 26911583
Drug: High (>2370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High (>2370 ng/L) and intermediate (806-2370 ng/L) NT-proBNP levels
Trial: 26912134
Drug: Selumetinib 75
RxNorm normalized name: Sélumétinib
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib 75 mg bd in combination with Cisplatin (25 mg/m²) and Gemcitabine (1000 mg/m²) administered on days 1 and 8 of a 21-day cycle.
Trial: 26913697
Drug: Maintenance lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Maintenance lenalidomide (5-10 mg/d for 12 cycles)
Trial: 26913697
Drug: Bendamustine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendamustine + rituximab (BR) induction without maintenance therapy
Trial: 26918124
Drug: Oral antithrombotic
RxNorm normalized name: antithrombin III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral antithrombotic drugs
Trial: 26920463
Drug: Epicutaneous immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epicutaneous immunotherapy using the Viaskin patch, dosage and duration not available
Trial: 26921281
Drug: Adjunctive balloon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive balloon angioplasty
Trial: 26922278
Drug: Candidates for
RxNorm normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candidates for LVAD treatment
Trial: 26923436
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) 400 mg/day with median starting ribavirin (RBV) dose of 800 mg (IQR: 400-1200)
Trial: 26923436
Drug: Sofosbuvir (SOF)
RxNorm normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sofosbuvir (SOF) 400 mg/day
Trial: 26923925
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) delivered by bachelor-level lay providers (BLPs)
Trial: 26923925
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment (CBT) delivered by PhD-level expert providers (PLPs)
Trial: 28288682
Drug: ADA discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ADA discontinuation
Trial: 26926644
Drug: Clindamycin intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin intravenous dosing regimens (5 mg/kg for ≤32 weeks PMA, 7 mg/kg for 32 to 40 weeks PMA, 9 mg/kg for >40 to 60 weeks PMA) administered every 8 hours
Trial: 26926676
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone in patients with RS ≤ 11
Trial: 26926676
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with RS > 25
Trial: 26926676
Drug: Chemotherapy in
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy in patients with RS 12 to 25
Trial: 26927672
Drug: Octanoic acid
RxNorm normalized name: Octanoic acid
DrugBank: Caprylic acid (DB04519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octanoic acid (OA) administered in doses ranging from 8 to 128 mg/kg
Trial: 26929418
Drug: Shorter regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shorter regimen using currently available TB drugs
Trial: 26929418
Drug: Bedaquiline-containing regimens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bedaquiline-containing regimens (all-oral and shortened version)
Trial: 26929648
Drug: Bevacizumab (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (10 mg/kg IV every 14 days) and Erlotinib (150 mg oral daily)
Trial: 26930146
Drug: HPV4 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HPV4 vaccine (1-3 doses)
Trial: 26930527
Drug: Omega-3 arm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 arm (930 mg EPA/750 mg DHA + 50 mg/d sertraline)
Trial: 26930527
Drug: Sertraline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline plus placebo arm
Trial: 26930627
Drug: Favipiravir (day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Favipiravir (day 0: 6,000 mg; day 1 to day 9: 2,400 mg/d)
Trial: 26933422
Drug: Nivolumab (anti-PD-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nivolumab (anti-PD-1 inhibitor) and RRx-001 (experimental anticancer agent)
Trial: 26934750
Drug: Anflu® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anflu® vaccine (2013-14 formulation: H1N1, H3N2, BYAM)
Trial: 26936878
Drug: Expressing 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expressing 500 mL/day by day 10
Trial: 26936878
Drug: Number of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Number of complete daily records
Trial: 26939629
Drug: Convection-enhanced delivery
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convection-enhanced delivery treatment of a therapeutic antibody
Trial: 26940080
Drug: Dexmedetomidine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine administered as a bolus of 1 μg/kg over 10 min followed by 1 μg/kg/h infusion, with possible increase to 2 μg/kg/h if necessary.
Trial: 26940080
Drug: Lower dexmedetomidine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dexmedetomidine dose and shorter sedation time for children younger than 1 year of age.
Trial: 26940383
Drug: Early home-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early home-based walking program implemented 1-month post-ICD implant.
Trial: 26942463
Drug: Enzastaurin 500
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin 500 mg orally once daily